Clinical Trial: Analysis of Sustained Benefit of Vedolizumab Combined with 5-ASA in the Treatment of Active UC (China)

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Analysis of Sustained Benefit of Vedolizumab Combined with 5-ASA in the Treatment of Active UC'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130556

Registration Time: 2026/08/21

Type: Observational study

Primary Sponsor: Beijing Chao-Yang Hospital, Capital Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337846

Published by HT Digital Content Services with permission from Health Daily Digest....